全文获取类型
收费全文 | 52863篇 |
免费 | 3247篇 |
国内免费 | 250篇 |
专业分类
耳鼻咽喉 | 520篇 |
儿科学 | 1025篇 |
妇产科学 | 657篇 |
基础医学 | 6915篇 |
口腔科学 | 1153篇 |
临床医学 | 5486篇 |
内科学 | 11556篇 |
皮肤病学 | 1059篇 |
神经病学 | 6411篇 |
特种医学 | 2576篇 |
外国民族医学 | 2篇 |
外科学 | 8744篇 |
综合类 | 312篇 |
一般理论 | 15篇 |
预防医学 | 2520篇 |
眼科学 | 802篇 |
药学 | 3117篇 |
中国医学 | 69篇 |
肿瘤学 | 3421篇 |
出版年
2023年 | 452篇 |
2022年 | 725篇 |
2021年 | 1501篇 |
2020年 | 913篇 |
2019年 | 1334篇 |
2018年 | 1515篇 |
2017年 | 1194篇 |
2016年 | 1420篇 |
2015年 | 1656篇 |
2014年 | 2083篇 |
2013年 | 2578篇 |
2012年 | 4134篇 |
2011年 | 4210篇 |
2010年 | 2476篇 |
2009年 | 2232篇 |
2008年 | 3557篇 |
2007年 | 3677篇 |
2006年 | 3387篇 |
2005年 | 3378篇 |
2004年 | 2953篇 |
2003年 | 2807篇 |
2002年 | 2557篇 |
2001年 | 522篇 |
2000年 | 423篇 |
1999年 | 486篇 |
1998年 | 518篇 |
1997年 | 392篇 |
1996年 | 319篇 |
1995年 | 248篇 |
1994年 | 241篇 |
1993年 | 179篇 |
1992年 | 181篇 |
1991年 | 165篇 |
1990年 | 129篇 |
1989年 | 114篇 |
1988年 | 120篇 |
1987年 | 75篇 |
1986年 | 96篇 |
1985年 | 90篇 |
1984年 | 117篇 |
1983年 | 93篇 |
1982年 | 88篇 |
1981年 | 67篇 |
1980年 | 66篇 |
1979年 | 59篇 |
1978年 | 55篇 |
1977年 | 57篇 |
1975年 | 57篇 |
1974年 | 54篇 |
1973年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
Kawedia JD Liu C Pei D Cheng C Fernandez CA Howard SC Campana D Panetta JC Bowman WP Evans WE Pui CH Relling MV 《Blood》2012,119(7):1658-1664
We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmaco-kinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti-asparaginase antibody levels on risk of relapse was assessed in 410 children who were treated on a front-line clinical trial for acute lymphoblastic leukemia and were evaluable for all pharmacologic measures, using multivariate analyses, adjusting for standard clinical and biologic prognostic factors. Dexamethasone clearance (mean ± SD) was higher (P = 3 × 10(-8)) in patients whose sera was positive (17.7 ± 18.6 L/h per m(2)) versus nega-tive (10.6 ± 5.99 L/h per m(2)) for anti-asparaginase antibodies. In multivariate analyses, higher dexamethasone clearance was associated with a higher risk of any relapse (P = .01) and of central nervous system relapse (P = .014). Central nervous system relapse was also more common in patients with anti-asparaginase antibodies (P = .019). In conclusion, systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies. Lower exposure to both drugs was associated with an increased risk of relapse. 相似文献
994.
995.
Lioure B Béné MC Pigneux A Huynh A Chevallier P Fegueux N Blaise D Witz B Delain M Cornillon J Luquet I Blanchet O Cornillet-Lefebvre P Carré M Hunault M Larosa F Lamy T Randriamalala E Ojeda-Uribe M Berthou C Fornecker L Harousseau JL Bouscary D Ifrah N Cahn JY;GOELAMS 《Blood》2012,119(12):2943-2948
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients. 相似文献
996.
Liersch R Gerss J Schliemann C Bayer M Schwöppe C Biermann C Appelmann I Kessler T Löwenberg B Büchner T Hiddemann W Müller-Tidow C Berdel WE Mesters R 《Blood》2012,119(22):5215-5220
Osteopontin (OPN) is a glycoprotein that is secreted by osteoblasts and hematopoietic cells. OPN suppresses the proliferation of hematopoietic stem cells in vitro and may regulate the hematopoietic stem cell pool. Increased serum OPN concentrations occur in chronic myeloid leukemia, multiple myeloma, and acute myeloid leukemia (AML). In the present study, we analyzed the prognostic impact of OPN in AML by investigating the expression and relevance of OPN in newly diagnosed AML patients from 2 large study groups (the German AML Cooperative Group and the Dutch-Belgian Hematology Oncology Cooperative group). IHC (n = 84), ELISAs of blood/BM sera (n = 41), and microarray data for mRNA levels (n = 261) were performed. Expression of OPN protein was increased in AML patients both in BM blasts (IHC) and in BM serum (ELISA) compared with healthy controls. Patients expressing high levels of OPN within the BM (IHC) experienced shortened overall survival (OS; P = .025). Multivariate analysis identified karyotype, blast clearance (day 16), and the level of OPN expression as independent prognostic factors for OS. This prompted us to analyze microarray data from 261 patients from a third cohort. The analysis confirmed OPN as a prognostic marker. In summary, high OPN mRNA expression indicated decreased event-free survival (P = .0002) and OS (P = .001). The prognostic role of OPN was most prominent in intermediate-risk AML. These data provide evidence that OPN expression is an independent prognostic factor in AML. 相似文献
997.
Romano E Cotari JW Barreira da Silva R Betts BC Chung DJ Avogadri F Fink MJ St Angelo ET Mehrara B Heller G Münz C Altan-Bonnet G Young JW 《Blood》2012,119(22):5182-5190
998.
999.